Business
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
- SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy - Response rate in patients
About this update from Soligenix, Inc.
[{"type":"text","content":"- SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy\n - Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold\n - Reinforces positive SGX301 primary endpoint treatment response demonstrating statistical significance after 6 weeks of therapy\n\n\n\n \n PRINCETON, N.J., April 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued treatment with SGX301 (synthetic hypericin) twice weekly for 12 weeks increased the positive response rate to 40% (p","length":1040,"tagName":"div"}]